Patents by Inventor Marcel Gubler

Marcel Gubler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IN VITRO NEPHROTOXICITY SCREENING ASSAY
    Publication number: 20230304089
    Abstract: The invention relates to methods for predicting the in vivo nephrotoxicity of a nucleic acid molecule, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of EGFR as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.
    Type: Application
    Filed: October 24, 2022
    Publication date: September 28, 2023
    Inventors: Marcel Gubler, Annie Moisan, Adrian B. Roth
  • In vitro nephrotoxicity screening assay
    Patent number: 11479818
    Abstract: The invention relates to methods for predicting the in vivo nephrotoxicity of a nucleic acid molecule, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of EGFR as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 25, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marcel Gubler, Annie Moisan, Adrian B. Roth
  • IN VITRO NEPHROTOXICITY SCREENING ASSAY
    Publication number: 20210405027
    Abstract: The invention relates to methods for predicting the in vivo nephrotoxicity of a drug substance, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of extracellular EGF as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 30, 2021
    Inventors: Marcel Gubler, Sabine Sewing, Annie Moisan, Adrian B. Roth
  • In vitro nephrotoxicity screening assay
    Patent number: 11105794
    Abstract: The invention relates to methods for predicting the in vivo nephrotoxicity of a drug substance, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of extracellular EGF as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: August 31, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marcel Gubler, Sabine Sewing, Annie Moisan, Adrian B. Roth
  • Chiral library screen
    Patent number: 10815481
    Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 27, 2020
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler
  • IN VITRO NEPHROTOXICITY SCREENING ASSAY
    Publication number: 20200109451
    Abstract: The invention relates to methods for predicting the in vivo nephrotoxicity of a nucleic acid molecule, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of EGFR as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.
    Type: Application
    Filed: June 16, 2017
    Publication date: April 9, 2020
    Inventors: Marcel Gubler, Annie Moisan, Adrian B. Roth
  • IN VITRO NEPHROTOXICITY SCREENING ASSAY
    Publication number: 20190265230
    Abstract: The invention relates to methods for predicting the in vivo nephrotoxicity of a drug substance, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of extracellular EGF as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.
    Type: Application
    Filed: June 16, 2017
    Publication date: August 29, 2019
    Inventors: Marcel Gubler, Sabine Sewing, Annie Moisan, Adrian B. Roth
  • Chiral Library Screen
    Publication number: 20170335323
    Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.
    Type: Application
    Filed: December 16, 2015
    Publication date: November 23, 2017
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler
  • Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
    Publication number: 20170008949
    Abstract: Herein is reported the use of a conjugate of a subunit of a multi-subunit structure and one biologically active entity for targeted delivery of the biologically active entity to the multi-subunit structure.
    Type: Application
    Filed: June 9, 2016
    Publication date: January 12, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Marcel Gubler, Sabine Imhof-Jung
  • FBPase inhibitors for diabetes
    Patent number: 7868030
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in the application and which can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: January 11, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marcel Gubler, Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Rudolf E. Minder, Brigitte Schott, Hans P. Wessel
  • Benzodioxepine derivatives
    Patent number: 7459480
    Abstract: This invention relates to compounds of the formula wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACC? inhibitors.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: December 2, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Luca Claudio Gobbi, Marcel Gubler, Werner Neidhart, Matthias Heinrich Nettekoven
  • New FBPase inhibitors for diabetes
    Publication number: 20070281979
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in the application and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: May 30, 2007
    Publication date: December 6, 2007
    Inventors: Marcel Gubler, Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Rudolf E. Minder, Brigitte Schott, Hans P. Wessel
  • Benzodioxepine derivatives
    Publication number: 20050113374
    Abstract: This invention relates to compounds of the formula wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACC? inhibitors.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 26, 2005
    Inventors: Luca Gobbi, Marcel Gubler, Werner Neidhart, Matthias Nettekoven
  • Treatment of metabolic diseases with soraphen derivatives
    Publication number: 20030144345
    Abstract: The present invention relates to the use of Soraphen derivatives and pharmaceutically acceptable esters thereof, for the treatment and/or prophylaxis of diseases which are associated with ACC&bgr; activity and/or fatty acid oxidation such as diabetes, obesity and dyslipidemia.
    Type: Application
    Filed: July 17, 2002
    Publication date: July 31, 2003
    Inventors: Marcel Gubler, Jacques Mizrahi